Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania. Show more

Location: Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States | Website: https://larimartx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

342.4M

52 Wk Range

$1.61 - $9.50

Previous Close

$4.00

Open

$4.00

Volume

595,833

Day Range

$4.00 - $4.28

Enterprise Value

208.5M

Cash

138.5M

Avg Qtr Burn

-23.07M

Insider Ownership

1.07%

Institutional Own.

83.78%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.